Fumihiro Tanaka

Statistics

Publications

Citations

869

H-Index

Active since

2013

Affiliations

University of Occupational and Environmental Health Japan(Current)

Hospital Universitario Puerta de Hierro Majadahonda

McGill University Health Centre

Bristol-Myers Squibb (United States)

Shanghai Chest Hospital

Fumihiro Tanaka is an author at University of Occupational and Environmental Health Japan specializing in oncology, neoadjuvant chemotherapy, and medicine.

Publications per year

2013–2025

Publications

Perioperative Nivolumab in Resectable Lung Cancer

Tina Cascone, Mark M. Awad, Jonathan Spicer et al. · New England Journal of Medicine · 2024 · 447 citations · Full text

Medicine, Oncology, Surgery +17

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer

Patrick M. Forde, Jonathan Spicer, Mariano Provencio et al. · New England Journal of Medicine · 2025 · 160 citations

Medicine, Oncology, Surgery +15

LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC

Tina Cascone, Mark M. Awad, J.D. Spicer et al. · Annals of Oncology · 2023 · 100 citations · Full text

Medicine, Oncology, Pharmacology +12

Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.

Jonathan Spicer, Nicolas Girard, Mariano Provencio et al. · Journal of Clinical Oncology · 2024 · 60 citations

Medicine, Oncology, Pharmacology +16

Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial.

Jonathan Spicer, Patrick M. Forde, Mariano Provencio et al. · Journal of Clinical Oncology · 2023 · 24 citations

Medicine, Oncology, Surgery +17

1–5 of 10